← All trials
NCT04963413
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- May 31, 2023
- Completion date
- May 31, 2025
- First posted
- Jul 15, 2021
- Last posted
- Dec 2, 2021
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of FloridaLead sponsor
- University of FloridaOverall official - principal investigator
- Immunomic Therapeutics, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.